Redefining DIAGNOSTICS

Revolutionizing the efficient use of NGS (Next-Generation Sequencing) in precision diagnostics

Redefining accessible

Genomill Health is a precision diagnostics company with a mission to disrupt the use of molecular diagnostic tests – liquid biopsies and beyond. We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our novel patent-pending Geno1™ pre-sequencing technology, enabling unprecedented improvements in performance and scalability.

Reduced
cost

Increased
accuracy

Faster
turn-around-time

Geno1™

Driven by world-class research

Our Geno1™ technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and artificial intelligence.

It truly provides means for unprecedented scaling of liquid biopsies and beyond by tackling the three main drivers: cost, accuracy and turn-around-time.

Join our journey

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1™ for out-licensing and are continuously looking for new long-term partnerships within oncology and other verticals – such as tropical and infectious diseases, NIPT, antibiotic resistance.

Join us in harnessing a true game-changing technology!

Get in touch by emailing us at info@genomill.com!

Latest news

<font color="#57C1AC"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming to broaden adoption of its Geno1 technology, a barcoding-based method that it believes can enhance sequencing accuracy and lower costs…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics.